Jeff Yass’s aTyr Pharma ATYR Stock Holding History

Jeff Yass’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.9K	Sell	116,500 -46,400	-28%	-$30.3K	﹤0.01%	12691
2026 Q1	$127K	Sell	162,900 -13,600	-8%	-$11.5K	﹤0.01%	12168
2025 Q4	$138K	Sell	176,500 -9,900	-5%	-$8.13K	﹤0.01%	11244
2025 Q3	$134K	Buy	186,400 +66,900	+56%	+$303K	﹤0.01%	11369
2025 Q2	$606K	Buy	119,500 +35,400	+42%	+$139K	﹤0.01%	8730
2025 Q1	$254K	Buy	84,100 +73,200	+672%	+$267K	﹤0.01%	10436
2024 Q4	$39.5K	Buy	+10,900	New	+$33K	﹤0.01%	11768
2023 Q3	–	Sell	-55,100	Closed	-$119K	–	13170
2023 Q2	$119K	Buy	+55,100	New	+$120K	﹤0.01%	10805
2022 Q4	–	Sell	-98,400	Closed	-$295K	–	13887
2022 Q3	$295K	Sell	98,400 -11,300	-10%	-$37.9K	﹤0.01%	9839
2022 Q2	$310K	Buy	109,700 +2,600	+2%	+$9.4K	﹤0.01%	9485
2022 Q1	$573K	Buy	107,100 +76,900	+255%	+$436K	﹤0.01%	8627
2021 Q4	$226K	Sell	30,200 -13,500	-31%	-$113K	﹤0.01%	11191
2021 Q3	$397K	Buy	+43,700	New	+$261K	﹤0.01%	9962

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's ATYR Position: Q2 2026 in Review

Jeff Yass reduced its aTyr Pharma (ATYR) stake by 14% in Q2 2026, selling an estimated $78.2K and leaving 747,039 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #10172.

Jeff Yass first reported a position in ATYR in Q1 2017 and has held it in 17 quarters since. The position peaked at $5.23M in Q1 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Jeff Yass held 747,039 shares of aTyr Pharma worth $446K as of Q2 2026.
Jeff Yass sold 119,705 aTyr Pharma shares in Q2 2026, an estimated $78.2K.
aTyr Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10172 holding.
Jeff Yass first reported a position in aTyr Pharma in Q1 2017 and has held it in 17 quarters since.
Jeff Yass's aTyr Pharma position peaked at $5.23M in Q1 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.